Press Releases

Filters
March 23, 2004

Debiopharm´s Pamorelin Long Acting, Formulated Using Debio® PLGA Technology, receives Final Marketing Autorisation in Germany

Read more
March 4, 2004

Yakult Honsha files Initial Submission for Marketing Authorisation of Debiopharm´s Oxaliplatin in Japan

Read more
March 2, 2004

H3 Pharma Inc. Submits new drug application to FDA for Sanvar® IR

Read more
February 24, 2004

Dyax Corp. and Debiopharm S.A. report positive Results from Phase IIa Clinical Trial with DX-890 (EPI-hNE4) in Children with Cystic…

Read more
January 19, 2004

ELOXATIN™ submitted in the United States and in Europe for the adjuvant treatment of patients with colon cancer

Read more
January 12, 2004

Eloxatin™ (oxaliplatin for injection) approved in the United States for the 1st line treatment of metastatic colorectal cancer

Read more
January 7, 2004

ELOXATIN® is becoming a cornerstone therapy for the treatment of metastatic colorectal cancer in Europe

Read more
December 15, 2003

Debiopharm S.A. and Dyax Corp. granted orphan drug designation for DX-890 (EPI-HNE4) by U.S. FDA – Cystic Fibrosis designation

Read more
December 2, 2003

Debiopharm S.A. seeks New Partner to Commercialise Trelstar® (Triptorelin Pamoate) in the US, Canada and Mexico for the Treatment of…

Read more